[
  {
    "ts": null,
    "headline": "Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?",
    "summary": "Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 4.2% over the past month. Since...",
    "url": "https://finnhub.io/api/news?id=6a95dde6c4c6b1d0525536e6142ec61f5bd38deb984b8ee8f3856b3160920cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756216816,
      "headline": "Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?",
      "id": 136525695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 4.2% over the past month. Since...",
      "url": "https://finnhub.io/api/news?id=6a95dde6c4c6b1d0525536e6142ec61f5bd38deb984b8ee8f3856b3160920cea"
    }
  },
  {
    "ts": null,
    "headline": "Abbott’s Esprit BTK System gains CE mark for PAD treatment",
    "summary": "The stent is engineered to keep arteries open, deliver everolimus for vessel healing, and gradually dissolve over time.",
    "url": "https://finnhub.io/api/news?id=c435498463e09be34e5386976db21c180f165b3a4d446b9c003cc69d636f4b93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756199600,
      "headline": "Abbott’s Esprit BTK System gains CE mark for PAD treatment",
      "id": 136523942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The stent is engineered to keep arteries open, deliver everolimus for vessel healing, and gradually dissolve over time.",
      "url": "https://finnhub.io/api/news?id=c435498463e09be34e5386976db21c180f165b3a4d446b9c003cc69d636f4b93"
    }
  },
  {
    "ts": null,
    "headline": "Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment",
    "summary": "Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3",
    "url": "https://finnhub.io/api/news?id=21059fdb95d97d45590e52736be70ceceb1653f7169dfbc5efc65136c8c6d0e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756189740,
      "headline": "Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment",
      "id": 136523943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott's denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3",
      "url": "https://finnhub.io/api/news?id=21059fdb95d97d45590e52736be70ceceb1653f7169dfbc5efc65136c8c6d0e8"
    }
  }
]